专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP1397488A1 NOVEL COMPOUNDS FOR CHEMILUMINESCENSE PROCEDURES 有权
标题翻译： NEW试剂化学发光检测方法
公开(公告)号：EP1397488A1
公开(公告)日：2004-03-17
申请号：EP02735389.5
申请日：2002-05-28
申请人： Roche Diagnostics GmbH , F. HOFFMANN-LA ROCHE AG
发明人： HEINDL, Dieter , HERRMANN, Rupert , JOSEL, Hans-Peter , HUBER, Erasmus , KLAUSE, Ursula
IPC分类号： C12N9/18 , C12Q1/68 , C12N5/10 , C12N15/62 , C07K16/18 , G01N33/50 , G01N33/53 , A61K48/00 , A61K39/00
CPC分类号： C07D401/12 , C07D219/06 , C07D417/04 , C07D417/14 , C12Q1/28 , G01N33/533 , G01N33/582 , Y10S435/968 , Y10S436/80 , Y10S436/904
摘要： The present invention relates to a chemical compound comprising a light emitting moiety precursor (eg. acridine, luciferine) and a precursor of a leaving group (eg. oxazine, anilide), bound to each other by an amide or by an ester bond and characterized in that the leaving group precursor upon oxidation is converted into the leaving group. The invention also relates to compounds additionally comprising a coupling group to the use of such compounds for labeling of biomolecules and more generally to the use of such compounds in chemiluminescence detection procedures.

2. 发明授权

EP1397488B1 NOVEL COMPOUNDS FOR CHEMILUMINESCENSE PROCEDURES 有权
标题翻译： NEW试剂化学发光检测方法
公开(公告)号：EP1397488B1
公开(公告)日：2006-08-16
申请号：EP02735389.5
申请日：2002-05-28
申请人： Roche Diagnostics GmbH , F. HOFFMANN-LA ROCHE AG
发明人： HEINDL, Dieter , HERRMANN, Rupert , JOSEL, Hans-Peter , HUBER, Erasmus , KLAUSE, Ursula
IPC分类号： C12N9/18 , C12Q1/68 , C12N5/10 , C12N15/62 , C07K16/18 , G01N33/50 , G01N33/53 , A61K48/00 , A61K39/00
CPC分类号： C07D401/12 , C07D219/06 , C07D417/04 , C07D417/14 , C12Q1/28 , G01N33/533 , G01N33/582 , Y10S435/968 , Y10S436/80 , Y10S436/904
摘要： The present invention relates to a chemical compound comprising a light emitting moiety precursor (eg. acridine, luciferine) and a precursor of a leaving group (eg. oxazine, anilide), bound to each other by an amide or by an ester bond and characterized in that the leaving group precursor upon oxidation is converted into the leaving group. The invention also relates to compounds additionally comprising a coupling group to the use of such compounds for labeling of biomolecules and more generally to the use of such compounds in chemiluminescence detection procedures.

3. 发明公开

EP3156800A1 BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER 审中-公开
标题翻译：贝伐珠单抗联合治疗乳腺癌的血液生物标志物
公开(公告)号：EP3156800A1
公开(公告)日：2017-04-19
申请号：EP16184951.8
申请日：2011-07-18
申请人： F. Hoffmann-La Roche AG
发明人： DE HAAS, Sanne Lysbet , DELMAR, Paul , FOERNZLER, Dorothee , KLAUSE, Ursula , SCHERER, Stefan
IPC分类号： G01N33/574
CPC分类号： G01N33/6893 , A61K31/337 , A61K39/3955 , G01N33/57415 , G01N2333/475 , G01N2800/52
摘要： The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer, by adding bevacizumab (Avastin Ⓡ ) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the progression-free survival of the patient. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin Ⓡ ) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels in patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer.
摘要翻译：本发明提供了用于改善患有乳腺癌，特别是局部晚期复发或转移性HER-2阴性乳腺癌的患者的化疗方案的治疗效果的方法，通过将化疗方案加入贝伐单抗（阿瓦斯汀）相对于诊断患有乳腺癌的患者的对照水平，特别是局部晚期复发或转移性HER-2阴性乳腺癌的VEGFA，VEGFR2和PLGF中的一种或多种的表达水平，特别是血浆表达水平。具体而言，本发明提供了改善治疗效果的方法，其中治疗效果是患者的无进展存活。本发明进一步提供了评估患者对贝伐单抗（阿瓦斯汀）与化疗方案组合的敏感性或反应性的方法，其通过确定VEGFA中的一种或多种的表达水平，特别是血浆表达水平， VEGFR2和PLGF相对于诊断患有乳腺癌，特别是局部晚期，复发或转移性HER-2阴性乳腺癌的患者中的对照水平。

4. 发明授权

EP2596363B1 BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER 失效
标题翻译：贝伐珠单抗联合治疗乳腺癌的血液生物标志物
公开(公告)号：EP2596363B1
公开(公告)日：2017-01-18
申请号：EP11746191.3
申请日：2011-07-18
申请人： F. Hoffmann-La Roche AG
发明人： DE HAAS, Sanne Lysbet , DELMAR, Paul , FOERNZLER, Dorothee , KLAUSE, Ursula , SCHERER, Stefan
IPC分类号： G01N33/574
CPC分类号： G01N33/6893 , A61K31/337 , A61K39/3955 , G01N33/57415 , G01N2333/475 , G01N2800/52

5. 发明公开

EP1934612A1 ANTI-CCP AND ANTINUCLEAR ANTIBODIES IN DIAGNOSIS OF RHEUMATOID ARTHRITIS 审中-公开
标题翻译：抗CCP抗体和类风湿性关节炎抗核抗体诊断
公开(公告)号：EP1934612A1
公开(公告)日：2008-06-25
申请号：EP06818248.4
申请日：2006-10-04
申请人： Roche Diagnostics GmbH , F.HOFFMANN-LA ROCHE AG
发明人： KLAUSE, Ursula , SCHMOLKE, Susanne , ZOLG, Werner , LEHMANN, Hans-Peter
IPC分类号： G01N33/564
CPC分类号： G01N33/564 , G01N33/6887 , G01N2800/102
摘要： The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in the differential diagnosis of rheumatoid arthritis in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample both the concentration of anti-CCP and of antinuclear antibodies (ANA) correlating the concentrations determined to the diagnosis of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and ANA and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and ANA in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

6. 发明授权

EP1419386B1 VERFAHREN ZUR HERSTELLUNG VON PROTEIN-BELADENEN MIKROPARTIKELN 有权
标题翻译：用于生产加载蛋白质微粒
公开(公告)号：EP1419386B1
公开(公告)日：2006-07-12
申请号：EP02764836.9
申请日：2002-08-07
申请人： Roche Diagnostics GmbH , F.HOFFMANN-LA ROCHE AG
发明人： FINKE, Andreas , KLAUSE, Ursula , DONIE, Frederic , HERRMANN, Rupert , VON DER ELTZ, Herbert , SLUKA, Peter , JONA, Wolfgang
IPC分类号： G01N33/48 , A61K9/16 , A61K9/14 , G01N33/543
CPC分类号： G01N33/54326 , A61K9/1676 , G01N33/54353 , G01N33/545
摘要： The invention relates to a method for producing microparticles loaded with proteins. Said method is characterised in that the microparticles are loaded in suspension in strongly alkaline conditions. The invention also relates to microparticles which can be produced according to said method and to the use of same in a binding test e.g. in an immunoassay.

7. 发明公开

EP2817631A1 HBV IMMUNOCOMPLEXES FOR RESPONSE PREDICTION AND THERAPY MONITORING OF CHRONIC HBV PATIENTS 审中-公开
标题翻译： HBV-IMMUNKOMPLEXE ZUR REAKTIONSVORHERSAGE UNDTHERAPIEÜBERWACHUNGBEI CHRONISCHEN HBV-PATITENTEN
公开(公告)号：EP2817631A1
公开(公告)日：2014-12-31
申请号：EP13706944.9
申请日：2013-02-18
申请人： Roche Diagnostics GmbH , F.Hoffmann-La Roche AG , Academic Medical Center at the University of Amsterdam
发明人： KLAUSE, Ursula , HIPP, Berthold , GRUNERT, Veit Peter , UPMEIER, Barbara , LOPATIN, Uri , De Neit, Annikki , REESINCK, Henk , ZAAIJER, Hans
IPC分类号： G01N33/576 , G01N33/68
CPC分类号： G01N33/56983 , G01N33/564 , G01N33/5761 , G01N2333/02 , G01N2800/52
摘要： The present invention relates to a method for identifying a subject suffering from hepatitis B virus (HBV) infection as being susceptible to interferon treatment, said method comprising the steps of a) determining, in a sample of said subject, the amount of HBV immune complexes, b)comparing the amount of HBV immune complexes obtained in step a) to a reference value, and c) identifying a subject suffering from HBV infection as being susceptible to interferon treatment based on the result of the comparison made in step b). The present invention further relates to the use of the determination of the amount of HBV immune complexes in a sample from a subject suffering from HBV infection and of a detection agent for HBV immune complexes for identifying a subject suffering from HBV infection as being susceptible to interferon treatment. Furthermore, the present invention relates to a device and a kit allowing identifying a subject suffering from HBV infection as being susceptible to interferon treatment.
摘要翻译：本发明涉及用于鉴定患有乙型肝炎病毒（HBV）感染的受试者易于进行干扰素治疗的方法，所述方法包括以下步骤：a）在所述受试者的样品中测定HBV免疫复合物的量 b）将步骤a）中获得的HBV免疫复合物的量与参考值进行比较，以及c）根据步骤b）中进行的比较结果，鉴定患有HBV感染的受试者易于进行干扰素治疗。本发明还涉及确定来自患有HBV感染的受试者的样本中的HBV免疫复合物的量的用途以及用于鉴定患有HBV感染的受试者对于干扰素敏感的HBV免疫复合物的检测剂治疗。此外，本发明涉及允许将患有HBV感染的受试者识别为易于进行干扰素治疗的装置和试剂盒。

8. 发明公开

EP1419386A1 VERFAHREN ZUR HERSTELLUNG VON PROTEIN-BELADENEN MIKROPARTIKELN 有权
标题翻译：用于生产加载蛋白质微粒
公开(公告)号：EP1419386A1
公开(公告)日：2004-05-19
申请号：EP02764836.9
申请日：2002-08-07
申请人： Roche Diagnostics GmbH , F.HOFFMANN-LA ROCHE AG
发明人： FINKE, Andreas , KLAUSE, Ursula , DONIE, Frederic , HERRMANN, Rupert , VON DER ELTZ, Herbert , SLUKA, Peter , JONA, Wolfgang
IPC分类号： G01N33/48 , A61K9/16 , A61K9/14 , G01N33/543
CPC分类号： G01N33/54326 , A61K9/1676 , G01N33/54353 , G01N33/545
摘要： The invention relates to a method for producing microparticles loaded with proteins. Said method is characterised in that the microparticles are loaded in suspension in strongly alkaline conditions. The invention also relates to microparticles which can be produced according to said method and to the use of same in a binding test e.g. in an immunoassay.

9. 发明授权

EP2606362B1 AN ASSAY FOR MEASUREMENT OF ANTIBODIES BINDING TO A THERAPEUTIC MONOCLONAL ANTIBODY 有权
标题翻译：分析法的抗体测量结合治疗性单克隆抗体
公开(公告)号：EP2606362B1
公开(公告)日：2015-09-30
申请号：EP11746230.9
申请日：2011-08-17
申请人： Roche Diagnostics GmbH , F.Hoffmann-La Roche AG
发明人： GRUNERT, Veit Peter , KLAUSE, Ursula , KUBALEC, Pavel , ROTHFUSS, Matthias , UPMEIER, Barbara
IPC分类号： C40B30/04 , G01N33/68
CPC分类号： G01N33/6854 , C40B30/04 , G01N2800/52

10. 发明公开

EP2606362A1 AN ASSAY FOR MEASUREMENT OF ANTIBODIES BINDING TO A THERAPEUTIC MONOCLONAL ANTIBODY 有权
标题翻译：分析法的抗体测量结合治疗性单克隆抗体
公开(公告)号：EP2606362A1
公开(公告)日：2013-06-26
申请号：EP11746230.9
申请日：2011-08-17
申请人： Roche Diagnostics GmbH , F.Hoffmann-La Roche AG
发明人： GRUNERT, Veit Peter , KLAUSE, Ursula , KUBALEC, Pavel , ROTHFUSS, Matthias , UPMEIER, Barbara
IPC分类号： G01N33/68
CPC分类号： G01N33/6854 , C40B30/04 , G01N2800/52
摘要： The invention relates to an immunoassay method for determination of an anti- antibody (anti- AB) in vitro in a sample from a patient treated with a therapeutic monoclonal antibody (TmAB). The method comprises the steps of (a) providing an F(ab) fragment of said TmAB bound to a solid phase, (b) incubating the solid phase provided in (a) with the sample, thereby binding the anti- AB to the solid phase via the F(ab) fragment, (c) incubating the solid phase obtained in (b) with a monoclonal antibody that binds to the anti- AB, (d) detecting the monoclonal antibody bound in (c) and thereby determining the anti- AB in the sample. The invention also concerns a method for the determination of antigen specific antibodies of a particular immunoglobulin class by means of an immunoassay in an array format in which the detection of an anti- AB to a TmAB in a sample provided from a patient treated with said TmAB is determined in vitro. Also disclosed is the use of such method for detection of an anti- antibody and in the identification of a patient who is at risk to develop an adverse drug reaction (ADR) during treatment with a TmAB.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式